Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Clinical trial NCT06187506 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06187506
- Sponsor
- Fudan University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-18
- Primary completion
- 2026-09-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.